Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1Phase 1 1

Status

Recruiting 3Active not recruiting 2

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Genitourinary 5

Conditions

Prostatic Neoplasms 43Metastatic Castration-resistant Prostate Cancer 5Prostatic Diseases 3Kidney Neoplasms 3Urogenital Neoplasms 2Prostatic Neoplasms, Castration-Resistant 2Neoplasms by Site 2Neoplasms 2Genital Neoplasms, Male 2Carcinoma, Renal Cell 2Thrombocytopenia 1Renal Insufficiency 1Prostate Cancer Metastatic 1PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy 1Neoplasm Metastasis 1Metastatic Hormone Naive Prostate Cancer 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Metastatic Castration Resistant Prostate Cancer (mCRPC) 1Metastatic Castration Resistant Prostate Cancer 1Metastatic Castrate Resistant Prostate Cancer (mCRPC) 1Male Urogenital Diseases 1Liver Neoplasms 1High-Risk Localized Prostate Cancer 1Glioma 1Glioblastoma 1Genital Diseases, Male 1Disease 1Cytopenia 1Clear-cell metastatic renal cell carcinoma 1Carcinoma, Hepatocellular 1

Interventions

Abiraterone Acetate 7enzalutamide 6olaparib 5Prednisone 5Pluvicto 5Docetaxel 5radium Ra 223 dichloride 4darolutamide 4cabazitaxel 3Prednisolone 3testosterone 17 beta-cypionate 2fludarabine 2abiraterone 2Nivolumab 2Cyclophosphamide 2Androgen Antagonists 2sipuleucel-T 1rucaparib 1poly ICLC 1pamiparib 1niraparib 1lactitol 1fludarabine phosphate 1fluciclovine F-18 1enfortumab vedotin 1ebastine 1copanlisib 1cabozantinib 1bempegaldesleukin 1avelumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Metastatic Castration-resistant Prostate Cancer × Pluvicto × Clear all
NCT05682443 2026-05-22

PRESERVE-006

OncoC4, Inc.

Phase 1/2 Active not recruiting
148 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT06866938 2026-01-06

ReaLuP

Hospices Civils de Lyon

Phase 2 Recruiting
58 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT06514521 2025-12-30

Post Marketing Study on Pluvicto in Korea

Novartis

Recruiting
278 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT05613894 2025-10-31

CaboLu

University of Utah

Phase 1 Recruiting
33 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT05340374 2025-04-06

LuCAB

Peter MacCallum Cancer Centre, Australia

Phase 1/2 Active not recruiting
35 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡